{"prompt": "['Novartis', 'Confidential', 'Page 45', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Follow-', 'Period', 'Screen', 'Placebo Run-in', 'Treatment', 'Notes', 'up', 'Visit Number (Site visits)', '1', '101', '199', '201', '202', '203', '204', 'TD', '299', '301', 'Follow-up Visit 301 is only applicable for', 'patients not participating in the safety study.', 'Visit 199 and Visit 201 occur on the same', 'Treatment Week', '-3', '-1', '0', '0', '2', '4', '8', 'TD', '12', '16', 'day.', 'Treatment Day', '-21', '-7', '1', '1', '14', '28', '56', '84', '112', 'Record deaths', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Contact IRT', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'Randomize patient through IRT', 'S', 'Assess and dispense rescue', '*dispense SABA only', 'SABA to be used on an as-', 'S*', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S**', 'needed basis', '**assess SABA only', 'Dispense study drug', 'S', 'S', 'S', 'S', 'S', 'Patients will be instructed to take study drug', 'in the morning.', 'Assess compliance with study', 'drug (count tablets in returned', 'S', 'S', 'S', 'S', 'S', 'S', 'bottles)', 'In-clinic witnessed study drug', 'X', 'X', 'X', 'X', 'X', 'Complete Dosage Administration Record', 'intake', '(DAR)-Visit - at site visit.', 'Complete Study Drug Dosage', 'Administration Record-', 'X', 'X', 'Complete DAR- Summary at each indicated', 'visit to record compliance', 'Summary page', 'Complete Study Disposition', 'X', 'page (screening)', 'Complete Study Disposition', 'X', 'page (run-in)', 'Complete Study Disposition', 'X', 'page (end of treatment )', 'Complete Study Disposition', 'X', 'For patients not participating in the safety', 'page (follow-up)', 'study.', 'Complete Withdrawal of', 'X', 'X', 'X']['Novartis', 'Confidential', 'Page 46', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Follow-', 'Period', 'Screen', 'Placebo Run-in', 'Treatment', 'Notes', 'up', 'Visit Number (Site visits)', '1', '101', '199', '201', '202', '203', '204', 'TD', '299', '301', 'Follow-up Visit 301 is only applicable for', 'patients not participating in the safety study.', 'Visit 199 and Visit 201 occur on the same', 'Treatment Week', '-3', '-1', '0', '0', '2', '4', '8', 'TD', '12', '16', 'day.', 'Treatment Day', '-21', '-7', '1', '1', '14', '28', '56', '84', '112', 'informed consent form (if patient', 'withdraws consent)', 'Re-screening of patients is permitted once.', 'Once a patient enters the placebo run-in', 'period, the patient may not be re-', 'Re-screening of patient', 'X', 'screened. If a patient is re-screened, a new', 'informed consent (and assent if applicable)', 'must be obtained.', 'Appointment for next clinic visit', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'Dispense patient card', 'S', 'Discuss optional participation in', 'S', 'safety study', 'Collect patient card', 'S*', 'S', '*', 'If participating in the safety study.', 'Abbreviations: TD (treatment discontinuation), ICF (informed consent form), ACQ-5 (asthma control questionnaire-5), AQLQ+12 (asthma quality of life questionnaire for', '12 years and older,', 'eDiary/ePEF (electronic peak expiratory flow), ECG (electrocardiogram), RAST (radioallergosorbent test),', 'HbA1c (hemoglobulin A1c),', 'TRT (interactive response technology).']\n\n###\n\n", "completion": "END"}